{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:03:51Z","timestamp":1770318231447,"version":"3.49.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) assigns a high-risk score to patients who develop secondary hematologic malignancies following solid tumors, indicating an increased risk of non-relapse mortality (NRM). This study aimed to evaluate the impact of prior solid tumors on outcomes after hematopoietic stem cell transplantation (HSCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From a cohort of 2,382 patients who underwent HSCT for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) between January 2014 and July 2024, we included 43 (1.8%) with a history of prior solid tumors and 82 matched controls for analysis by 1:2 propensity score matching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The solid tumor cohort predominantly comprised breast cancer (48.8%). With a median follow-up of 31.0 months, only one patient exhibited post-transplant relapse or metastasis of the solid tumor. Compared to the control group, patients with solid tumors exhibited higher ECOG scores (\u2265 2: 23.1% vs. 9.5%, P = 0.049), lower platelet counts (35.5 vs. 72\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L, P = 0.010), a higher incidence of complex karyotypes (16.3% vs. 3.7%, P = 0.031). No significant differences were noted in 3-year overall survival (OS) (64.3% vs. 71.9%, P = 0.468), leukemia-free survival (LFS) (57.6% vs. 70.8%, P = 0.218), graft-versus-host disease\/relapse-free survival (GRFS) (43.3% vs. 53.0%, P = 0.359) and NRM (23.9% vs. 11.7%, P = 0.246). In an exploratory landmark analysis, the solid tumor cohort appeared to have significantly lower OS (P = 0.030), LFS (P = 0.009), and GRFS (P = 0.038) from 2 years after transplantation. Multivariable analysis identified age greater than 55 years, baseline platelet counts less than 50\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L as significant predictors of inferior OS and LFS in solid tumor patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with hematologic diseases secondary to solid tumors showed no significant increase in overall transplantation risk. However, their adverse clinical characteristics and reduced long-term survival rates beyond 2 years post-transplantation, underscore the need to refine HCT-CI scoring and improve management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1727469","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:23:14Z","timestamp":1770268994000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of prior solid tumor on outcomes of hematopoietic stem cell transplantation for hematologic malignancies: a propensity score-matched study"],"prefix":"10.3389","volume":"17","author":[{"given":"Jieya","family":"Luo","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyang","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Air Force Medical Center, Fourth Military Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]},{"name":"Haihe Laboratory of Cell Ecosystem, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Cao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e851","DOI":"10.1097\/hs9.0000000000000851","article-title":"Primary cancer matters in therapy-related myeloid neoplasm patients receiving allogeneic hematopoietic cell transplantation: A study from the chronic Malignancies working party of the ebmt","volume":"7","author":"Robin","year":"2023","journal-title":"Hemasphere"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193599","article-title":"Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/biomedicines12051054","article-title":"Therapy-related myeloid neoplasm: biology and mechanistic aspects of Malignant progression","volume":"12","author":"Travaglini","year":"2024","journal-title":"Biomedicines"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100584","DOI":"10.1016\/j.blre.2019.06.001","article-title":"Therapy-related acute lymphoblastic leukemia: where do we stand with regards to its definition and characterization","volume":"37","author":"Aldoss","year":"2019","journal-title":"Blood Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/life14030309","article-title":"Recent advances towards the understanding of secondary acute myeloid leukemia progression","volume":"14","author":"Auerbach","year":"2024","journal-title":"Life (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1493728","article-title":"Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation","volume":"60","author":"D\u2019Angelo","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (Hct)-specific comorbidity index: A new tool for risk assessment before allogeneic hct","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.197","article-title":"Impact of comorbidity indexes on non-relapse mortality","volume":"22","author":"Xhaard","year":"2008","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34517","article-title":"Transplantation for myeloid neoplasms with antecedent solid tumor","volume":"129","author":"Portuguese","year":"2023","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.102","article-title":"Current and emerging strategies for the prevention of graft-versus-host disease","volume":"11","author":"Choi","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: A report from the Mount Sinai acute gvhd international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: A study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of aml in adults: 2022 recommendations from an international expert panel on behalf of the eln","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute lymphoblastic leukemia, version 2.2024, nccn clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01229-z","article-title":"Impact of frontline treatment approach on outcomes in patients with secondary aml with prior hypomethylating agent exposure","volume":"15","author":"Short","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00616-3","article-title":"Chemotherapy-induced thrombocytopenia: literature review","volume":"14","author":"Gao","year":"2023","journal-title":"Discov Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/146532401753174043","article-title":"Immune reconstitution following hematopoietic stem-cell transplantation","volume":"3","author":"Novitzky","year":"2001","journal-title":"Cytotherapy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2015.1009156","article-title":"Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy","volume":"47","author":"Dan","year":"2015","journal-title":"Ann Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/genes11070749","article-title":"Genetic and genomic landscape of secondary and therapy-related acute myeloid leukemia","volume":"11","author":"Higgins","year":"2020","journal-title":"Genes (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19432","article-title":"Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer","volume":"205","author":"Pourhassan","year":"2024","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.004","article-title":"Outcome and risk factors for therapy-related myeloid neoplasms treated with allogeneic stem cell transplantation in Japan","volume":"26","author":"Kida","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217460","article-title":"Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"612","author":"Li","year":"2025","journal-title":"Cancer Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843420.50062.9b","article-title":"S132: tolerability and efficacy of the first-in-class anti-Cd47 antibody magrolimab combined with azacitidine in frontline patients with tp53-mutated acute myeloid leukemia: phase 1b results","volume":"6","author":"Daver","year":"2022","journal-title":"HemaSphere"},{"key":"B30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of sabatolimab (Mbg453) in combination with hypomethylating agents (Hmas) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (Vhr\/Hr-Mds) and acute myeloid leukemia (Aml): final analysis from a phase Ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01061-9","article-title":"Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of Tp53 and Inferior outcome","volume":"35","author":"Barnea Slonim","year":"2021","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"B33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-020-0316-3","article-title":"Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype","volume":"10","author":"Samra","year":"2020","journal-title":"Blood Cancer J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.122","article-title":"Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment","volume":"30","author":"Sevcikova","year":"2016","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01129-1","article-title":"Eln risk stratification and outcomes in secondary and therapy-related aml patients consolidated with allogeneic stem cell transplantation","volume":"56","author":"Jentzsch","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012565","article-title":"Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"key":"B37","doi-asserted-by":"publisher","first-page":"19282","DOI":"10.1038\/s41598-025-95356-5","article-title":"Survival outcomes in secondary and primary acute lymphoblastic leukemia: A systematic review and meta-analysis","volume":"15","author":"Abedini","year":"2025","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01794-4","article-title":"Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"57","author":"Rodr\u00edguez-Arbol\u00ed","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35125","article-title":"Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China","volume":"155","author":"Dou","year":"2024","journal-title":"Int J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06658-5","article-title":"Allogeneic hematopoietic cell transplantation in patients with a hematologic Malignancy and a prior history of breast cancer","volume":"194","author":"Doney","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-05041-0","article-title":"Allogeneic stem cell transplantation in patients with a prior history of prostate cancer","volume":"102","author":"Palmieri","year":"2023","journal-title":"Ann Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/jog.15954","article-title":"Therapy-related myeloid neoplasms after treatment for ovarian cancer: A retrospective single-center case series","volume":"50","author":"Matsuoka","year":"2024","journal-title":"J Obstet Gynaecol Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02192-0","article-title":"Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (All) compared to de-novo all-a report from the ebmt registry","volume":"59","author":"Sadowska-Klasa","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25395","article-title":"Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation","volume":"94","author":"Lee","year":"2019","journal-title":"Am J Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283468","article-title":"Secondary acute myeloid leukemia: time to turn the page","volume":"109","author":"R\u00e9cher","year":"2024","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024248","article-title":"Approaching a therapeutic inflection point for flt3-mutated aml","volume":"145","author":"Perl","year":"2025","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","article-title":"Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead","volume":"17","author":"Nadiminti","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414573","article-title":"Validation of the hematopoietic cell transplantation-specific comorbidity index: A prospective, multicenter gitmo study","volume":"120","author":"Raimondi","year":"2012","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.338","article-title":"Long-term follow-up of therapy-related myelodysplasia and aml patients treated with allogeneic hematopoietic cell transplantation","volume":"51","author":"Finke","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41408-025-01263-3","article-title":"Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia","volume":"15","author":"Pullarkat","year":"2025","journal-title":"Blood Cancer J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02194-w","article-title":"The role of cpx-351 in the acute myeloid leukemia treatment landscape: mechanism of action, efficacy, and safety","volume":"85","author":"Pagano","year":"2025","journal-title":"Drugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1727469\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:23:15Z","timestamp":1770268995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1727469\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2026.1727469"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1727469","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1727469"}}